DA
IONS icon

DCF Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

DCF Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,500
Closed -$45.3K – 87
2025
Q1 		$45.3K Buy
+1,500
New +$49.1K 0.02% 83

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCF Advisers's IONS Position: Q1 2026 in Review

DCF Advisers reduced its Ionis Pharmaceuticals (IONS) stake by 46% in Q1 2026, selling an estimated $3.71M and leaving 56,000 shares worth $4.21M. The position accounts for 1.12% of the portfolio, ranked #23.

DCF Advisers first reported a position in IONS in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.15M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • DCF Advisers held 56,000 shares of Ionis Pharmaceuticals worth $4.21M as of Q1 2026.
  • DCF Advisers sold 47,000 Ionis Pharmaceuticals shares in Q1 2026, an estimated $3.71M.
  • Ionis Pharmaceuticals made up 1.12% of DCF Advisers's portfolio in Q1 2026, its #23 holding.
  • DCF Advisers first reported a position in Ionis Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • DCF Advisers's Ionis Pharmaceuticals position peaked at $8.15M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.